Clinical trials: Alzheimer's
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
The main purpose of this study is to build upon the evidence captured in the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS; NCT02420756) trial to include valuable information regarding patient-reported outcomes and…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT2 (NCT02781220)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Utah
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology
The main purpose of this study is to explore the impact of an amyloid positron emission tomography and computed tomography (PET/CT) scan on physician diagnosis and management, including drug management and care practices, for…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT (NCT02778971)
- Testing
- [18F]Flutemetamol
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Utah
Mild Cognitive Impairment
DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Alzheimer's Disease
The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in…
- Trial name
- DIGITAL (NCT05844488)
- Testing
- PrecivityAD
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Indiana University
Transcranial Random Noise Stimulation (tRNS), Electroencephalography
Transcranial Random Noise (tRNS) for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial
To investigate the treatment effect of Transcranial random noise (tRNS) on Alzheimer patients, and the underlying neural mechanism by EEG.
- Conditions
- Transcranial Random Noise Stimulation (tRNS), Electroencephalography, Alzheimer Disease, BPSD (Behavioral and Psychological Symptoms of Dementia)
- Trial name
- NCT07827196
- Testing
- High frequency transcranial random noise
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Medical University
Agitation,Psychomotor, Disruptive Behavior
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of…
- Conditions
- Agitation,Psychomotor, Disruptive Behavior, Dementia, Alzheimer Disease
- Trial name
- NCT06217146
- Testing
- Medical Cannabis
- Where
- 3 sites in Israel
- Volunteers
- 24 people
- Sponsor
- M. H MediCane Ltd.
Alzheimer Disease
Finding Retinal Biomarkers in Alzheimer's Disease
CSF Alzheimer's disease (AD) biomarkers are the only one that reflect both Aβ and tau pathologies. There is increasing evidence for the presence of AD abnormalities in the retina of AD patients.
- Trial name
- FIREBALZ (NCT05067010)
- Testing
- Detailed ophthalmologic examination
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Frontotemporal Lobar Degeneration, Alzheimer Disease
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
The investigators will compare [18F]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched…
- Conditions
- Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
- Trial name
- NCT05456503
- Testing
- [18F]-PI-2620
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease, Insomnia
Quetiapine for the Treatment of Insomnia in Alzheimer's Disease
The primary hypothesis is that quetiapine will improve sleep in persons with Alzheimer's Disease (AD), with higher doses producing greater total sleep time and sleep efficiency.
- Trial name
- NCT00232570
- Testing
- quetiapine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Vermont
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mild Alzheimer's Disease
Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients
Eligible patients will undergo this open label initial safety and feasibility study investigating the use of 6 g/day sodium oxybate in mild AD.
- Trial name
- ALD (NCT00706186)
- Testing
- Sodium Oxybate
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Clayton Sleep Insititute
Alzheimer's Disease, Healthy Volunteer
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
This study is designed to obtain basic information on three PET imaging tracers developed to detect tau pathology in the brain. In this study, healthy control participants and participants with AD will be studied.
- Trial name
- NCT02187627
- Testing
- [11C]RO6924963, [11C]RO6931643, [18F]RO6958948
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Mild Cognitive Impairment, Alzheimer Disease
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2
To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Type2 Diabetes
- Trial name
- NCT03933696
- Testing
- Tailored Lighting Intervention
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer Disease
Bathing Persons With Alzheimer's Disease aT Home (The BATH Study)
This study will evaluate the effectiveness of a 3-week reminiscence intervention applied during bathing persons with Alzheimer's disease (AD) in decreasing resistiveness to care (RTC), relieving patient discomfort, and improving…
- Trial name
- NCT00062569
- Testing
- Bathing Support Intervention (BSI), Caregiver reminiscence with coaching
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Nursing Research (NINR)
Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI)
Positive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain Function
This randomized study tests whether a new multicomponent Positive Psychology program can improve cognition and wellbeing in older adults at the earliest stages of dementia-related decline.
- Conditions
- Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
- Trial name
- NCT07289061
- Testing
- Positive Psychology Intervention, Treatment as usual (TAU)
- Where
- Greece
- Volunteers
- 128 people
- Sponsor
- Aristotle University Of Thessaloniki
Alzheimer Disease, Cognitive Impairment
Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium…
- Trial name
- NCT01453569
- Testing
- Sodium oligo-mannurarate 600mg, Sodium oligo-mannurarate 900mg
- Where
- 24 sites in China
- Volunteers
- 255 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Dementia
Physical Activity Training Program for Patients With Alzheimer's Dementia
The purpose of this study is to determine if a home based physical activity training program for patients with Alzheimer's dementia has effects on clinical and neurobiological parameters.
- Trial name
- MOTODEM (NCT02196545)
- Testing
- Exercise
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Technische Universität Dresden
Alzheimers Disease
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
The goal of the trial is to see if the Safety and Tolerability of X/T+X/T-EC combined with currently treated Lecanemab participants with Alzheimer's Disease compared with placebo.
- Trial name
- NCT07212062
- Testing
- X/T + X-EC, Lecanemab 10 mg/kg
- Volunteers
- 60 people
- Sponsor
- Neurology Office of South Florida